Novo Nordisk's semaglutide drugs face significant Medicare price reductions under CMS negotiation rules starting 2027, but new indications could drive future revenue growth.
The federal government lowers obesity drug prices and expands Medicare coverage, impacting millions of patients and primary care providers with new access and cost structure.
New Medicare drug price negotiations under the Inflation Reduction Act cut costs for 15 major medications, saving Medicare $12 billion annually.
Comprehensive 2026 outlook on U.S. healthcare and insurance sector covering AI adoption, Medicare Advantage growth, pharmaceutical scrutiny, market consolidations, and emerging health equity focus.
New Medicare drug price negotiations reduce government costs on 15 high-spend medications, including cancer and diabetes treatments, saving $12 billion annually.
The Trump administration finalizes agreements reducing Medicare prices for 15 drugs, aiming to save billions and impact Medicare Part D plans and drug affordability policies.
Pharmaceutical companies agree to significant Medicare drug price cuts under Trump administration, projecting billions in savings with impacts on Medicare Part D and drug affordability.
CMS unveils the GENERous Medicaid payment model introducing MFN drug pricing, alongside expanded Trump administration drug pricing agreements and key regulatory updates for 2026.
Novo Nordisk and Eli Lilly agree to lower GLP-1 drug prices in exchange for expanded Medicare and Medicaid coverage, marking a major shift in U.S. drug pricing and access.
The looming deadline for drugmakers to comply with the Most Favored Nation drug pricing policy raises concerns over potential disruptions to Medicare Part D, highlighting regulatory and market risks for U.S. drug pricing and federal entitlement programs.
